124 studies found for:    Open Studies | niaid
Show Display Options
Rank Status Study
1 Recruiting Interferon Responses in Eczema Herpeticum
Conditions: Atopic Dermatitis;   Eczema Herpeticum;   Herpes Simplex Infections;   Eczema Vaccinatum
Intervention:
2 Not yet recruiting Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Condition: Liver Transplant
Intervention: Procedure: Immunosuppression withdrawal
3 Recruiting Subcutaneous Immunotherapy for Mouse in Adults
Conditions: Asthma;   Perennial Allergic Rhinitis,
Intervention: Biological: Mouse Allergenic Extract
4 Not yet recruiting Integrase and Maraviroc Intensification for Neurocognitive Dysfunction (InMIND)
Condition: HIV Infections
Interventions: Drug: Placebo for maraviroc (MVC);   Drug: Placebo for dolutegravir (DTG);   Drug: Dolutegravir (DTG);   Drug: Maraviroc (MVC)
5 Recruiting Registry for Asthma Characterization and Recruitment 2
Condition: Asthma
Intervention:
6 Not yet recruiting Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
Conditions: Asthma;   Asthma Exacerbations
Intervention:
7 Not yet recruiting Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Condition: Kidney Transplant
Interventions: Biological: Infliximab;   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Thymoglobulin;   Drug: Acetaminophen;   Drug: Loratadine;   Biological: Placebo for Infliximab;   Drug: Prednisone;   Drug: Diphenhydramine
8 Not yet recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
9 Not yet recruiting Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Conditions: Liver Transplant Recipient;   Living Donor (of the Respective Liver Transplant Recipient)
Interventions: Biological: darTregs;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Immunosuppression (IS) Withdrawal;   Procedure: Study Mandated Procedures
10 Not yet recruiting Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
Condition: HIV Infections
Intervention: Biological: VRC01
11 Not yet recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
12 Not yet recruiting Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX®-GP HIV-1 DNA vaccine;   Biological: Interleukin-12 (IL-12) DNA adjuvant;   Biological: Placebo
13 Recruiting Autologous Polyclonal Tregs for Lupus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Intervention: Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
14 Recruiting Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Condition: HIV Infections
Interventions: Drug: MK-2048A IVR (Low Dose);   Drug: MK-2048A IVR (Original Dose)
15 Not yet recruiting Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo
16 Recruiting A Safety and Immune Response Study of 2 Experimental HIV Vaccines
Condition: HIV Infection
Interventions: Biological: ALVAC-HIV;   Biological: Bivalent Subtype C gp120/MF59®;   Biological: ALVAC-HIV (vCP2438) Placebo;   Biological: Bivalent gp120/MF59® Placebo
17 Recruiting Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN1Δ30;   Biological: Placebo;   Biological: rDEN2Δ30-7169
18 Recruiting Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048
Condition: HIV Infections
Interventions: Device: Vicriviroc (MK-4176) Intravaginal Ring (IVR);   Device: MK-2048 IVR;   Device: MK-2048A IVR;   Device: Placebo IVR
19 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
20 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years